525 related articles for article (PubMed ID: 33673213)
1. Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme.
Tilak M; Holborn J; New LA; Lalonde J; Jones N
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33673213
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
[TBL] [Abstract][Full Text] [Related]
3. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Stommel JM; Kimmelman AC; Ying H; Nabioullin R; Ponugoti AH; Wiedemeyer R; Stegh AH; Bradner JE; Ligon KL; Brennan C; Chin L; DePinho RA
Science; 2007 Oct; 318(5848):287-90. PubMed ID: 17872411
[TBL] [Abstract][Full Text] [Related]
4. Aberrant
Al-Ghabkari A; Huang B; Park M
Cells; 2024 Jan; 13(3):. PubMed ID: 38334610
[TBL] [Abstract][Full Text] [Related]
5. Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.
Zhang Y; Kim J; Mueller AC; Dey B; Yang Y; Lee DH; Hachmann J; Finderle S; Park DM; Christensen J; Schiff D; Purow B; Dutta A; Abounader R
Cell Death Differ; 2014 May; 21(5):720-34. PubMed ID: 24440911
[TBL] [Abstract][Full Text] [Related]
6. PKC signaling in glioblastoma.
do Carmo A; Balça-Silva J; Matias D; Lopes MC
Cancer Biol Ther; 2013 Apr; 14(4):287-94. PubMed ID: 23358475
[TBL] [Abstract][Full Text] [Related]
7. Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology.
Rogers AE; Le JP; Sather S; Pernu BM; Graham DK; Pierce AM; Keating AK
Oncogene; 2012 Sep; 31(38):4171-81. PubMed ID: 22179835
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma.
Scherschinski L; Prem M; Kremenetskaia I; Tinhofer I; Vajkoczy P; Karbe AG; Onken JS
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055167
[TBL] [Abstract][Full Text] [Related]
9. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
10. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract][Full Text] [Related]
11. Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme.
Tuncel G; Kalkan R
Med Oncol; 2018 Aug; 35(9):122. PubMed ID: 30078108
[TBL] [Abstract][Full Text] [Related]
12. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells.
Vouri M; An Q; Birt M; Pilkington GJ; Hafizi S
Oncotarget; 2015 Jun; 6(18):16183-97. PubMed ID: 25980499
[TBL] [Abstract][Full Text] [Related]
13. EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase.
Wang SD; Rath P; Lal B; Richard JP; Li Y; Goodwin CR; Laterra J; Xia S
Oncogene; 2012 Dec; 31(50):5132-43. PubMed ID: 22310282
[TBL] [Abstract][Full Text] [Related]
14. Silencing of PROS1 induces apoptosis and inhibits migration and invasion of glioblastoma multiforme cells.
Che Mat MF; Abdul Murad NA; Ibrahim K; Mohd Mokhtar N; Wan Ngah WZ; Harun R; Jamal R
Int J Oncol; 2016 Dec; 49(6):2359-2366. PubMed ID: 27840905
[TBL] [Abstract][Full Text] [Related]
15. Heparan Sulfate Synthesized by
Ohkawa Y; Wade A; Lindberg OR; Chen KY; Tran VM; Brown SJ; Kumar A; Kalita M; James CD; Phillips JJ
Mol Cancer Res; 2021 Jan; 19(1):150-161. PubMed ID: 33028660
[TBL] [Abstract][Full Text] [Related]
16. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.
Szerlip NJ; Pedraza A; Chakravarty D; Azim M; McGuire J; Fang Y; Ozawa T; Holland EC; Huse JT; Jhanwar S; Leversha MA; Mikkelsen T; Brennan CW
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3041-6. PubMed ID: 22323597
[TBL] [Abstract][Full Text] [Related]
18. Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma.
Walsh AM; Kapoor GS; Buonato JM; Mathew LK; Bi Y; Davuluri RV; Martinez-Lage M; Simon MC; O'Rourke DM; Lazzara MJ
Mol Cancer Res; 2015 Aug; 13(8):1227-37. PubMed ID: 25934697
[TBL] [Abstract][Full Text] [Related]
19. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
